HER2扩增结直肠癌靶向治疗进展与挑战
本文综述HER2扩增/过表达作为RAS野生型转移性结直肠癌可成药生物标志物的预后与预测价值,介绍其分子结构、患者临床特征、诊断方法及评估抗HER2治疗现状与前景的关键临床试验;多个HER2靶向方案已纳入NCCN和ESMO指南,FDA近期批准图卡替尼联合曲妥珠单抗及德曲妥珠单抗用于经治HER2阳性转移性结直肠癌。
要点
- 约6%的RAS野生型转移性结直肠癌患者存在HER2扩增/过表达,是重要的可成药生物标志物。
- HER2的预后与预测意义仍有争议,但抗HER2治疗在HER2阳性转移性结直肠癌中显示有前景的结果。
- 多个HER2靶向方案已纳入NCCN和ESMO指南,FDA近期批准图卡替尼联合曲妥珠单抗及德曲妥珠单抗用于经治患者。
核心结论
- HER2扩增/过表达在约6%的RAS野生型转移性结直肠癌患者中被识别,已确立为重要且可成药的生物标志物。
- HER2的预后和预测意义仍有争议,但抗HER2治疗在HER2阳性转移性结直肠癌中显示出有前景的结果。
- 多个HER2靶向方案现已纳入美国国家综合癌症网络(NCCN)和欧洲肿瘤内科学会(ESMO)指南。
研究设计与样本
- 综述,探讨HER2作为结直肠癌生物标志物的预后与预测价值,描述其分子结构、HER2改变患者的临床特征、诊断方法及评估其作为转移性结直肠癌治疗靶点当前与未来作用的最相关临床试验。
主要发现
- 约6%的RAS野生型转移性结直肠癌患者存在HER2扩增/过表达。
- 结直肠癌是成人发病率第三常见癌症,也是欧洲癌症相关死亡第二常见原因。
- 转移性结直肠癌预后仍差,治疗基于标准化疗联合抗表皮生长因子受体(用于RAS野生型肿瘤)或抗血管内皮生长因子,或对错配修复缺陷肿瘤采用免疫治疗。
- 美国食品药品监督管理局(FDA)近期批准图卡替尼(联合曲妥珠单抗)和德曲妥珠单抗用于既往治疗的HER2阳性转移性结直肠癌患者。
关键数值与推荐
- HER2扩增/过表达被确定为约6%的RAS野生型转移性结直肠癌患者的生物标志物。
- NCCN和ESMO指南纳入多个HER2靶向方案。
- FDA批准图卡替尼联合曲妥珠单抗及德曲妥珠单抗用于经治HER2阳性转移性结直肠癌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colorectal cancer is the third most common cancer in terms of incidence rate in adults and the second most common cause of cancer-related death in Europe. Despite an increase in overall survival throughout the years, the prognosis of metastatic colorectal cancer remains poor. Until recently, its treatment was based on the use of standard chemotherapy combined with, anti-epidermal growth factor receptor (for RAS wild-type tumors) or anti-vascular endothelial growth factor, or immunotherapy for tumors with mismatch repair deficiency. Over the last years, precision medicine has become a challenge in oncology and there has been an increasing development of biomarker-driven therapies for metastatic colorectal cancer leading to better outcomes for specific molecular subgroups of patients. Human epidermal growth factor receptor 2 (HER2) amplification/overexpression has been identified in about 6 % of patients with RAS wild-type metastatic CRC and established as an important and drugable biomarker. Its prognostic and predictive implications are still debated but HER2 becoming a therapeutic target with promising results of anti-HER2 therapies for HER2-positive metastatic CRC. Multiple HER2-targeted regimens are now part of National Comprehensive Cancer Network and European Society for Medical Oncology guidelines with two recent Food and Drug Administration approvals for previously treated HER2-positive metastatic colorectal cancer for tucatinib (in combination with trastuzumab) and for trastuzumab-deruxtecan in patients with previously treated HER2-positive metastatic colorectal cancer. This review explores the prognostic and predictive value of HER2 as a biomarker in CRC, describing its molecular structure, the clinical characteristics of patients with HER2 alterations, diagnostic approaches and the most relevant clinical trials assessing its current and future role as a therapeutic target in metastatic colorectal cancer.
引用
- Pizzamiglio M, Soulabaille A, Lahlou W, et al. Advances and challenges in targeted therapies for HER2-amplified colorectal cancer. Eur J Cancer. 2025. PMID: 40311507. doi:10.1016/j.ejca.2025.115471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。